Figure 3 Overview of the ketotifen effects on EAE immunopathogenesis. The graphical abstract illustrates the main findings reported by Pinke et al. (2019): a striking reduction of EAE prevalence observed after early administration of ketotifen fumarate (0.4 mg/kg) on EAE mice. The protective role of this mast cell stabilizer drug was associated with blood-CNS barrier normalization and the subsequent reduction of EAE pathological features on the CNS despite the presence of a typical encephalitogenic response in peripheral lymphoid organs. EAE: Experimental autoimmune encephalomyelitis; CNS: central nervous system; DCs: dendritic cells; IFN-γ: interferon γ; IL: interleukin.